

# Hutchison Whampoa Limited

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 013)**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.6% owned subsidiary of Hutchison Whampoa Limited.

As at the date of the announcement, the Directors of Hutchison Whampoa Limited are:

**Executive Directors:**

Mr. LI Ka-shing (*Chairman*)  
Mr. LI Tzar Kuoi, Victor (*Deputy Chairman*)  
Mr. FOK Kin-ning, Canning  
Mrs. CHOW WOO Mo Fong, Susan  
Mr. Frank John SIXT  
Mr. LAI Kai Ming, Dominic  
Mr. KAM Hing Lam

**Non-executive Directors:**

Mr. George Colin MAGNUS  
Mr. William SHURNIAK

**Independent Non-executive Directors:**

The Hon. Sir Michael David KADOORIE  
Mr. Holger KLUGE  
Mr. William Elkin MOCATTA  
*(Alternate to The Hon. Sir Michael David Kadoorie)*  
Mr. Simon MURRAY  
Mr. OR Ching Fai, Raymond  
Mr. WONG Chung Hin  
*(also Alternate to Mr. Simon Murray)*

Hong Kong, 23 March 2007



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited  
(AIM: HCM)**

**Director's Shareholding**

**London: Friday, 23 March 2007:** Hutchison China MediTech Limited ("Chi-Med") was informed on 22 March 2007 that Mr. Christian Hogg, Executive Director and Chief Executive Officer of Chi-Med, purchased 100,000 ordinary shares of US\$1 each in Chi-Med (the "Shares") at a price of 172p each on 22 March 2007.

Following this purchase, Mr. Hogg is beneficially interested in 100,000 Shares, representing approximately 0.2% of the current issued share capital of Chi-Med.

**Ends**

**Enquiries**

**Chi-Med Telephone: +852 2121 8200**

Christian Hogg, CEO

**Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571**

Anthony Carlisle Mobile: +44 (0) 7973 611 888  
Yvonne Alexander Mobile: +44 (0) 7866 610 682

**About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.